Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor ... $1 billion-plus by 2026 if approved with a broad label. Overall, the antibody cut the annual asthma ...

Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat ... test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

Am J Health Syst Pharm. 2006;63(8):712-714. Drug information specialists are pharmacists whose primary responsibility is the provision of drug information. As with any specialty, formalized ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing course, with a potentially ...

Background It is unclear if type-2 inflammation is associated with accelerated lung function decline in individuals with asthma and chronic obstructive pulmonary disease (COPD). We tested the ...